IP Verse

Novel Polymorphic Forms Of Perindopril (L)-Arginine And Process For The Preparation Thereof - EP2682388

The patent EP2682388 was granted to Mylan Laboratories on Jan 10, 2018. The application was originally filed on Jun 22, 2009 under application number EP13003519A. The patent is currently recorded with a legal status of "Revoked".

EP2682388

MYLAN LABORATORIES
Application Number
EP13003519A
Filing Date
Jun 22, 2009
Status
Revoked
Apr 3, 2020
Grant Date
Jan 10, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOEFER & PARTNER PATENTANWALTE MBBOct 10, 2018HOEFER & PARTNER PATENTANWALTE MBB -
LES LABORATOIRES SERVIEROct 10, 2018- -

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0496588
DESCRIPTIONUS4508729
DESCRIPTIONUS4914214
DESCRIPTIONUS6696481
DESCRIPTIONWO2007099216
DESCRIPTIONWO2007099217
OPPOSITIONEP1354873
OPPOSITIONEP2161257
OPPOSITIONEP2318365
OPPOSITIONWO2007099216
OPPOSITIONWO2007099217
OPPOSITIONWO2009157018
SEARCHWO2007099216
SEARCHWO2007099217

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- R. HILFIKER, Polymorphism: in the Pharmaceutical Industry, WILEY-VCH, (2006), pages 259 - 285-
OPPOSITION- anonymous, "Pentanes", Wikipedia, the free encyclopedia, (20171216), URL: https://en.wikipedia.org/wiki/Pentanes, XP055523254-
OPPOSITION- "Kristallisieren", ORGANIKUM, Berlin, VEB Deutscher Verlag der Wissenschaften, (19880000), pages 32 - 33, XP055522964-
OPPOSITION- L. LEFEBVRE, "Optimization de cristallisation en solution de deux composes organiques en vue de leur purification", THÈSE UNIVERSITÉ DE ROUEN, (20060301), pages 7-9,51 - 52,73, XP055281174-
OPPOSITION- Loïc LEFEBVRE, "Optimisation of crystallisation of two organic compounds from solution for the purpose of their purification", THÈSE UNIVERSITÉ DE ROUEN, (20060301), pages 7-9, 51 - 52,73, XP055281174-
OPPOSITION- B.C. HANCOCK et al., "What is the True Solubility Advantage for Amorphous Pharmaceuticals?", Pharmaceutical Research, (20000400), vol. 17, no. 4, pages 397 - 404, XP009086748
OPPOSITION- K. Nagapudi et al, "Amorphous Active Pharmaceutical Ingrédients in Preclinical Studies. K. Nagapudi, J. Jona", Curr. Bioactive Compounds, (20081200), vol. 4, pages 213 - 224, XP055078333

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents